Quick Answer
Chemours Co reported Total Revenue of $5.81 billion for fiscal year 2025.
Chemours Co — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $5.81B +0.4% |
$5.78B -4.9% |
$6.08B -11.0% |
$6.83B +7.7% |
$6.34B +27.7% |
$4.97B -10.1% |
| Revenue (ASC 606) | $5.81B +0.4% |
$5.78B -4.9% |
$6.08B -11.0% |
$6.83B +7.7% |
$6.34B +27.7% |
$4.97B -10.1% |
| Net Income | -$386.00M -659.4% |
$69.00M +127.3% |
-$253.00M -143.8% |
$578.00M -4.9% |
$608.00M +177.6% |
$219.00M +521.2% |
| Diluted EPS | -$2.57 -658.7% |
$0.46 +127.1% |
-$1.70 -146.6% |
$3.65 +1.4% |
$3.60 +172.7% |
$1.32 +512.5% |
| Total Assets | $7.38B -1.8% |
$7.51B -8.9% |
$8.24B +7.9% |
$7.64B +1.2% |
$7.55B +6.6% |
$7.08B -2.4% |
| Cash and Equivalents | $670.00M -6.0% |
$713.00M -40.7% |
$1.20B +9.2% |
$1.10B -24.1% |
$1.45B +31.3% |
$1.10B +17.2% |
| Long-Term Debt | $4.07B +0.2% |
$4.06B +1.8% |
$3.99B +11.1% |
$3.59B -3.6% |
$3.72B -7.0% |
$4.00B -0.5% |
| Stockholders Equity | $566.00M -0.9% |
$571.00M -23.8% |
$749.00M -32.3% |
$1.11B +2.4% |
$1.08B +33.0% |
$813.00M +18.0% |
| R&D Expense | $108.00M -0.9% |
$109.00M +0.9% |
$108.00M -8.5% |
$118.00M +10.3% |
$107.00M +15.1% |
$93.00M +16.2% |
| Gross Profit | $902.00M -21.0% |
$1.14B -12.3% |
$1.30B -19.4% |
$1.62B +17.0% |
$1.38B +29.4% |
$1.07B +0.4% |
| Shares Outstanding | 149.89M +0.3% |
149.43M +0.6% |
148.59M +0.1% |
148.50M -7.8% |
161.05M -2.3% |
164.92M +0.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.50B | -0.9% | -7.4% |
| Revenue (ASC 606) | September 30, 2025 | $1.50B | -0.9% | -7.4% |
| Net Income | September 30, 2025 | $60.00M | +287.5% | +115.7% |
| Diluted EPS | September 30, 2025 | $0.40 | +281.8% | +115.7% |
| Total Assets | September 30, 2025 | $7.57B | +1.5% | +1.1% |
| Cash and Equivalents | September 30, 2025 | $613.00M | +2.9% | +22.1% |
| Long-Term Debt | September 30, 2025 | $4.10B | +2.8% | -0.1% |
| Stockholders Equity | September 30, 2025 | $298.00M | -53.7% | +25.7% |
| R&D Expense | September 30, 2025 | $26.00M | -10.3% | -7.1% |
| Gross Profit | September 30, 2025 | $233.00M | -18.5% | -16.2% |
| Shares Outstanding | September 30, 2025 | 149.87M | +0.3% | +0.1% |
- Chemours Co reported Total Revenue of $5.81 billion for fiscal year 2025.
- Chemours Co showed an increase of +0.4% in Total Revenue compared to the prior fiscal year.
- Chemours Co reported Revenue (ASC 606) of $5.81 billion for fiscal year 2025.
- Chemours Co showed an increase of +0.4% in Revenue (ASC 606) compared to the prior fiscal year.
- Chemours Co reported Net Income of -$386.00 million for fiscal year 2025.
- Chemours Co showed a decrease of -659.4% in Net Income compared to the prior fiscal year.
- Chemours Co reported Diluted EPS of $2.57 per share (loss) for fiscal year 2025.
- Chemours Co showed a decrease of -658.7% in Diluted EPS compared to the prior fiscal year.
- Chemours Co reported Total Assets of $7.38 billion for fiscal year 2025.
- Chemours Co showed a decrease of -2.2% in Total Assets compared to the prior fiscal year.
- Chemours Co reported Cash and Equivalents of $670.00 million for fiscal year 2025.
- Chemours Co showed a decrease of -6.0% in Cash and Equivalents compared to the prior fiscal year.
- Chemours Co reported Long-Term Debt of $4.10 billion for fiscal year 2025.
- Chemours Co showed a decrease of -0.1% in Long-Term Debt compared to the prior fiscal year.
- Chemours Co reported Stockholders Equity of $250.00 million for fiscal year 2025.
- Chemours Co showed a decrease of -8.8% in Stockholders Equity compared to the prior fiscal year.
- Chemours Co reported R&D Expense of $108.00 million for fiscal year 2025.
- Chemours Co showed a decrease of -0.9% in R&D Expense compared to the prior fiscal year.
- Chemours Co reported Gross Profit of $902.00 million for fiscal year 2025.
- Chemours Co showed a decrease of -21.0% in Gross Profit compared to the prior fiscal year.
- Chemours Co reported Shares Outstanding of 149.89 million shares for fiscal year 2025.
- Chemours Co showed an increase of +0.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: